EurekAlert!

Long way up: Rethink diseases in light of phase separation and phase transition

With an increasingly profound understanding of the interplay between condensate biology and diseases, there is a poised acceleration of classical drug development processes, catalyzing breakthroughs ...
The Manila Times

Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer

DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation ...
EurekAlert!

Reversible manipulation of liquid-liquid phase separation using a chemical-based chemiDroplet

Chemidroplet is a chemical tool, that fused the BTB-containing domain to the multivalent DNA binding domain (DBD) and intrinsically disordered regions (IDRs) to readily control the LLPS of these ...
The Manila Times

Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate

Dewpoint Therapeutics, Inc., a biotechnology company pioneering condensate-modulating therapeutics, today announced the ...
GEN

Stabilizing Synthetic Gene Circuits Using Transcriptional Condensates

Genetic engineers can design and assemble sophisticated gene circuits to program cells with new functions, but important signaling molecules can become diluted as these cells grow and divide, causing ...
Pharmabiz

Dewpoint Therapeutics doses first patient in phase 1a/2a clinical trial of DPTX3186 to treat advanced solid tumours

Dewpoint Therapeutics doses first patient in phase 1a/2a clinical trial of DPTX3186 to treat advanced solid tumours: Boston Monday, February 9, 2026, 18:00 Hrs [IST] Dewpoint Ther ...